Skip to main content
Fig. 4 | EJNMMI Radiopharmacy and Chemistry

Fig. 4

From: Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®

Fig. 4

Effects of chemotherapy on tumor and normal tissue uptake of [89Zr]ZrIV-labeled chDAB4 using different bifunctional chelators. Representative whole-body PET images of a single mouse from each group (n = 5) during the course of the experiment are shown. Color scale indicates relative extent of tissue uptake of radioactivity. Arrows in white at Day 8 time point indicate tumors in right flank of each mouse (a). Tumor uptake of the [89Zr]ZrIV-labeled antibodies during the course of the experiment was quantified and expressed as Percent Injected Dose per gram (%ID/g) using PMOD® software (b). The biodistribution of [89Zr]ZrIV-labeled DFO-NCS (DFO) and DFOSq conjugates of chDAB4 was measured using the HIDEX counter in tumor and organs taken from mice on Days 3 and 8 (c). On Day 3, %ID/g derived from physical γ-counts measured in different organs were expressed as a ratio for tumor to blood, tumor to bone, or tumor to liver (d). All data points are means ± SD

Back to article page
\